1.Therkildsen C, et al. (2018). Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol. DOI:10.1002/1878-0261.12325 2.Ju J Y , et al. (2018). Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas[J]. The American Journal of Surgical Pathology. DOI:10.1097/PAS.0000000000001141 3.Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer[J]. Journal of Clinical Oncology. 2019. DOI:10.1200/JCO.18.00283 4.Morgan Rouprêt, et al. (2005). Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma[J]. Urology. DOI:10.1016/j.urology.2005.01.019 5.Iyer G, et al. (2017). Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. J Clin Oncol. DOI:10.1200/JCO.2017.35.15_suppl.4511 6.Huang, et al. (2018). Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome[J]. Bladder cancer. DOI:10.3233/BLC-180180 7.Dharmesh G , et al. (2018). Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook[J]. Therapeutics and Clinical Risk Management. DOI:10.2147/TCRM.S158753 8.Metcalfe M J , et al. (2017). Universal Point-of-Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma[J]. The Journal of Urology. DOI:10.1016/j.juro.2017.08.002